Although response to lenalidomide among MDS patients with del(5q) and tyrosine kinase inhibitor (TKI) resistance among chronic myeloid leukemia (CML) patients did not correlate with CMA findings, additional copy number aberrations identified by CMA and TP53 mutations/17p deletions are associated with disease progression and worse prognosis [79,80]. The gene discussed is TP53; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.